Lymphadenectomy in NSCLC With and Without Adjuvant Therapy

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

250 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-05-13

Study Completion Date

2025-05-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Adjuvant therapy in patients affected by NSCLC is indicated in surgically treated cases of N2 disease, while the actual guidelines reported the possibility of a case-by-case decision in case of N1 involvement.

On the other hand, the actual categorization of patients based on the hilar or mediastinal involvement (N1 or N2) risks to be too ineffective and straightforward for prognosis prediction and an indication of adjuvant treatments. This issue was underlined in the 8th TNM proposal for the N sub-classification, with a final proposal of different subgroups based on the number of involved stations. However, the IASLC committee noted that this proposal presented some limits due overlapping or not statistical significance among some survival curves, so the proposal was not adopted in the staging system. Moreover, the committee stated that the lack of information regarding some data such as the number of the resected or the metastatic nodes might affect the results and limited other proposals.

The objectives of this study are:

* To evaluate the prognostic role of the kind of lymphadenectomy, the number of the resected and/or metastatic lymph nodes in surgically treated N positive patients in terms of survival.
* To evaluate the indication and the role of adjuvant treatments in these patients.
* To identify patients with increased risk of early recurrence or poor survival based on the lymph node involvement characteristics In particular, data will be collect in a prospective database including clinical and pathological data, kind of lymphadenectomy, number of resected nodes, number of metastatic nodes, kind and schedule of adjuvant therapy and follow-up status

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Segmentectomy vs Lobectomy

NCT06180239

Non-small Cell Lung Cancer Stage I Surgery

ACTIVE_NOT_RECRUITING

Molecular Signature From Tumor to Lymph Nodes

NCT04677205

Lung Cancer Stage IIIA-cN2 Operated With Curative Intent +2 more

RECRUITING

Maximizing Lymph Node Dissection on Fresh and Fixed Lung Cancer Resection Specimens

NCT06252129

Lung Cancer Lymph Node Metastasis Pathologic Processes

RECRUITING NA

Radical Resection With Contralateral Lymph Node Dissection for Clinical N3 NSCLC

NCT07003490

NSCLC, Non Small Cell Lung Cancer

RECRUITING NA

Lymph Node Removal in Treating Patients With Stage I or Stage II Non-small Cell Lung Cancer

NCT00003831

Lung Cancer

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

NSCLC Lymph Node Metastases

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

lymphadenectomy

Lymphadenctomy according with ESTS guidelines

Intervention Type PROCEDURE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

adjuvant therapy

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Informed consent
* Age \>18 years
* Non-Small Cell Lung Cancer Histology
* Anatomical lung resection (segmentectomy, lobectomy or bilobectomy, pneumonectomy)
* Pre-operative CT and PET evaluation
* Preoperative and postoperative tumour board discussion
* Intraoperative lymph node assessment (minimum 3 mediastinal stations harvested)
* Lymph node metastases